Step 1 topics → General Pharmacology → ADME and Bioavailability

ADME and Bioavailability

USMLE Step 1 trap: Assumes IV drugs undergo first-pass and have F < 1. IV administration always yields 100% bioavailability by definition, since the drug enters systemic circulation directly.

ADME — absorption, distribution, metabolism, excretion — is the framework that explains what the body does to a drug, and USMLE Step 1 tests it across every organ system, not just in standalone pharmacology questions. Bioavailability (F) is the fraction of an administered dose that reaches systemic circulation unchanged. These concepts are foundational and show up embedded in vignettes about why a patient needs a different route, why a drug fails therapeutically, or why a dose must be adjusted in liver disease. You'll see them embedded in vignettes about why a patient needs a different route, why a drug fails therapeutically, or why a dose must be adjusted in liver disease.

The exam hits three angles: pure definition recall (F = AUC oral / AUC IV), mechanistic reasoning about first-pass metabolism, and clinical route-selection scenarios. The mechanistic angle is where most students lose points — they understand that 'first-pass is bad for oral drugs' but can't explain where it happens or why changing the route fixes it. The clinical angle tests whether you can translate that mechanism into a real decision: sublingual nitroglycerin, IV morphine, rectal diazepam.

The tricky part is that several misconceptions cluster around this topic and are specifically designed to trip up students on USMLE Step 1. Students frequently mislocate first-pass metabolism to the stomach, assume sublingual is just 'oral but dissolved faster,' and — critically — assume IV drugs can somehow lose bioavailability to metabolism. None of these are correct, and the distinctions matter in vignette answer choices.

From real student decks
54%have cards covering this topic
38%have mature cards

Common misconceptions

Common mistake
Wrong: IV drugs can have bioavailability less than 100% due to metabolism.
Right: IV administration always yields 100% bioavailability by definition, since the drug enters systemic circulation directly.
IV administration delivers drug directly into systemic venous circulation, so by definition F = 1 (100%) — there is no absorption step and no portal passage for first-pass to occur. Bioavailability is a property of the route, not the drug's metabolic fate after it's already in circulation. Post-absorption metabolism affects plasma half-life and clearance, not bioavailability itself.
Common mistake
Wrong: First-pass metabolism occurs in the stomach or intestinal lumen.
Right: First-pass metabolism occurs primarily in the intestinal wall and liver after oral absorption via the portal circulation.
First-pass metabolism does not occur in the stomach or gut lumen — it requires the drug to be absorbed first. After oral absorption across the intestinal epithelium, drug enters the portal vein and passes through the liver before reaching systemic circulation; both the intestinal wall (CYP3A4-rich) and the liver are the primary sites. This is why antacids or gastric pH changes don't directly alter first-pass effect.
Common mistake
Wrong: Sublingual drugs still undergo first-pass metabolism like oral drugs.
Right: Sublingual drugs drain into the superior vena cava, bypassing portal circulation and first-pass metabolism entirely.
Sublingual administration is fundamentally different from oral: the drug absorbs through the oral mucosa directly into the superior vena cava, completely sidestepping portal circulation. This means no intestinal wall metabolism, no hepatic first-pass — which is exactly why nitroglycerin is given sublingually (its oral bioavailability is near zero due to extensive first-pass). Don't conflate the route with oral just because both involve the mouth.
Common mistake
Gap: Unaware that rectal route partially avoids first-pass metabolism
Rectal administration partially bypasses first-pass metabolism because the inferior and middle rectal veins drain into the systemic circulation, not the portal vein.
Rectal administration is a partial bypass, not a complete one. The inferior and middle rectal veins drain into the internal iliac vein and then systemic circulation, avoiding the portal vein — but the superior rectal vein does drain into the portal system. So bioavailability via rectal route is higher than oral for high-first-pass drugs, but not as complete as sublingual or IV. This partial bypass is clinically relevant for drugs like diazepam given rectally in pediatric seizures.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the definition of bioavailability (F) and be able to calculate it using the AUC ratio: F = AUC(oral) / AUC(IV). Understand that F = 1 (100%) is the reference point for IV administration.
  2. Understand the first-pass metabolism pathway mechanistically: orally absorbed drug travels from the gut via portal circulation to the liver, where it is metabolized before reaching systemic circulation. Know that this occurs in the intestinal wall and liver — not the stomach.
  3. Apply route-of-administration knowledge clinically: recognize which routes bypass first-pass metabolism (sublingual, IV, transdermal, rectal-partial) and why a clinician would choose them for drugs with high first-pass effect.

Can you avoid these mistakes?

A patient with severe hepatic cirrhosis is prescribed oral morphine. Why might the bioavailability of oral morphine be unexpectedly HIGH in this patient compared to someone with normal liver function? What ADME concept explains this?
Nitroglycerin tablets are given sublingually rather than swallowed. Using your knowledge of first-pass metabolism and venous drainage, explain precisely why the sublingual route is necessary — where does the absorbed drug go, and what does it avoid?
A drug is administered both IV (100 mg) and orally (100 mg) in a pharmacokinetic study. The AUC for IV is 200 mg·h/L and the AUC for oral is 50 mg·h/L. What is the bioavailability of the oral formulation, and what is the most likely explanation for this value?
A patient cannot swallow and cannot receive IV medications. You need to give a benzodiazepine for seizure control. Which alternative route would you choose to maximize bioavailability while partially bypassing first-pass metabolism, and why is that route better than oral?

Related topics

Volume of Distribution (Vd) Clearance and Half-Life First-Order vs Zero-Order Elimination Loading and Maintenance Dosing

See how your Anki deck covers this topic.

Upload your deck for a free audit →